复方丹参联合瑞舒伐他汀治疗冠心病合并高脂血症的效果分析

Clinical analysis of salvia miltiorrhiza combined with rosuvastatin calcium in the treatment of coronary heart disease complicated with hyperlipidemia

目的:探讨复方丹参联合瑞舒伐他汀治疗冠心病合并高脂血症的临床疗效。方法:冠心病合并高脂血症患者166例,数表法随机分为实验组( n=88)和对照组(n =78)。两组患者均服用基础药物阿司匹林肠溶片(100 mg/次,1次/d)与欣康(40 mg/次,1次/d);对照组于晚餐后30 min口服瑞舒伐他汀(10 mg/次,1次/d),实验组患者在对照组基础上服用复方丹参滴丸(270 mg/次,3次/d),治疗时间均为6个月。比较两组患者的治疗总有效率;治疗前后甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、总胆固醇(TC);心输出量(CO)、左室射血分数(LVEF);血浆黏度、全血高切黏度、血小板聚集率和纤维蛋白原、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-β(IL-β)的变化;治疗前后心电图的改善情况;随访半年后统计不良心血管病并发症。结果:治疗后,对照组和实验组临床总有效率分别为43.6%、77.3%;心电图改善总有效率分别为47.4%、89.8%,组间比较差异均具有统计学意义(均 P<0.05);两组患者血脂与心功能指标均有不同程度改善。实验组所有观测指标均优于对照组,差异均有统计学意义(P<0.05);两组血清炎性因子在治疗后较治疗前都有所下降,且实验组下降程度更显著(P<0.05)。随访半年后,实验组患者总不良心血管事件发生率显著低于对照组(P <0.05)。结论:复方丹参联合瑞舒伐他汀治疗冠心病合并高脂血症,临床疗效良好,能降低血脂水平、改善心功能及改善血液流变学相关指标。

Objective: To investigate the clinical efficacy of compound salvia miltiorrhiza combined with rosuvastatin in the treatment of coronary heart disease complicated with hyperlipidemia. Methods: A total of 166 patients with coronary heart disease complicated with hyperlipidemia were randomly divided into experimental group( n =88) and control group( n =78).Both groups received the basic drug aspirin(100mg/time,once/24h)and Xinkang(40mg/time,once/24h).The control group received oral administration of rosuvastatin calcium tablets(10mg/time,once/24h) at 30 min after dinner.The experimental group took Compound Danshen Dripping Pills on the basis of the control group(270 mg/Times,3 times/d) for 6 months.The total effective rate of treatment was compared between the two groups,changes of triglyceride(TG),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),total cholesterol(TC),cardiac output(CO),left ventricle ejection fraction(LVEF),plasma viscosity,high blood viscosity of whole blood,Platelet aggregation rate and fibrinogen,high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α) and IL-β before and after treatment.Compare the improvement of ECG before and after treatment in the two groups of patients,follow-up after 6 months of statistical cardiovascular disease complications. Results: The total effective rate of the control group and the experimental group were 43.6% and 77.3%,respectively.The total effective rate of ECG improvement was 47.4% and 89.8%,respectively.The differences between the groups were statistically significant( P <0.05).The blood lipids and cardiac function indexes of the two groups were improved to different extents.All the observation indexes of the experimental group were better than the control group,and the differences were statistically significant( P <0.05).The serum inflammatory factors of the two groups were decreased after treatment,and the decrease of the experimental group was more significant( P <0.05).After 6 months follow-up,the incidence of total adverse cardiovascular events in the experimental group was significantly lower than that in the control group( P <0.05). Conclusion: Compound Danshen combined with rosuvastatin in the treatment of coronary heart disease with hyperlipidemia has good clinical efficacy,can lower blood lipid levels,improve heart function and improve blood rheology related indicators.